CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 128 enrolled
Drug / intervention
Pamiparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03333915
NCT03333915Phase 2Completed
CompareCT.gov

An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer

BeiGene·interventional·Posted Nov 7, 2017·Updated Feb 4, 2025

In Brief

A Phase 2 clinical trial evaluating Pamiparib for Advanced High-grade Ovarian Cancer and Triple Negative Breast Cancer. Completed, enrolled 128 participants across 6 sites.

Detailed Summary

This study is designed to evaluate the safety, tolerability, PKharmacokinetic profile and treatment effect of pamiparib in Chinese participants with advanced high-grade ovarian cancer (including fallopian cancer or primary peritoneal cancer) and triple negative breast cancer in phase I, and to evaluate the efficacy and safety of pamiparib in Chinese participants with recurrent epithelial ovarian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline breast cancer susceptibility gene 1/gene 2 (BRCA1/2) mutation in phase II.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 7, 2017
Enrollment StartDec 21, 2016
Primary CompletionAug 24, 2020
Study CompletionAug 11, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.7 years ago

Interventions

Pamiparibdrug

Pamiparib is provided as oral capsules